Carbamazepine Labeling To Advise Genetic Screen To Avoid Side Effect
Executive Summary
Labeling for carbamazepine drugs will be revised to recommend patients of Asian descent be genetically screened prior to starting therapy to help identify those at an increased risk of a serious side effect, FDA announced Dec. 12
You may also be interested in...
Warfarin Label Change Falls Short of Recommending Genetic Testing
FDA took warfarin one step into the world of personalized medicine Aug. 16 with labeling changes that inform patients and doctors about the usefulness of genetic testing before beginning therapy with the blood thinner
Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs
The agency’s projection that Medicare will spend $3.5bn on Leqembi in 2025 is nearly three times the level of sales that marketer Eisai is expecting for the drug in North and South America combined in its fiscal year 2026.
Biosimilar Substitution In Medicare Part D Formularies Mid-Year Established In Final Rule
Policy may be helpful in promoting acceptance of follow-ons in Medicare but is not expected to result in near-term savings to the program.